durvalumab

News

After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 drug durvalumab .

News

Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.